Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC.

The expiration of the HSR waiting period satisfies one of the regulatory conditions necessary for the completion of the transaction. The transaction remains subject to the satisfaction or waiver of other customary closing conditions, set forth in the merger agreement, including approval by Simulations Plus shareholders and receipt of certain regulatory approvals in France. Subject to the satisfaction or waiver of the remaining closing conditions, the transaction is currently expected to close in the second half of calendar 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.